Advertisement

Advertisement

ONCY Stock Latest News

Oncolytics Showcases Pelareorep Phase 2 mCRC Study Plans

Company AnnouncementsOncolytics Showcases Pelareorep Phase 2 mCRC Study Plans

Oncolytics to present REO 033 trial in progress abstract at ESMO

PremiumThe Fly

Oncolytics to present REO 033 trial in progress abstract at ESMO

2d ago

Oncolytics Biotech Updates GOBLET Gastrointestinal Cancer Study

PremiumCompany Announcements

Oncolytics Biotech Updates GOBLET Gastrointestinal Cancer Study

8d ago

Oncolytics should be bought amid recent weakness, says Lake Street

PremiumThe Fly

Oncolytics should be bought amid recent weakness, says Lake Street

8d ago

Oncolytics Biotech Extends Pelareorep Patent Protection Into Late 2040s

PremiumCompany Announcements

Oncolytics Biotech Extends Pelareorep Patent Protection Into Late 2040s

10d ago

Oncolytics provides intellectual property portfolio update

PremiumThe FlyOncolytics provides intellectual property portfolio update

10d ago

Oncolytics Biotech Highlights Pelareorep’s Tumor-Activating Potential

Company Announcements

Oncolytics Biotech Highlights Pelareorep’s Tumor-Activating Potential

23d ago

Oncolytics announces publication of data on pelareorep in liver cancer

The Fly

Oncolytics announces publication of data on pelareorep in liver cancer

23d ago

Oncolytics Advances Pelareorep Trial, Gains FDA Alignment

PremiumCompany Announcements

Oncolytics Advances Pelareorep Trial, Gains FDA Alignment

24d ago

Oncolytics reports accelerating enrollment in REO 033 study

PremiumThe Fly

Oncolytics reports accelerating enrollment in REO 033 study

24d ago

Oncolytics Biotech Reports Positive Pelareorep Preclinical Results

PremiumCompany Announcements

Oncolytics Biotech Reports Positive Pelareorep Preclinical Results

1M ago

Oncolytics reports pelareorep preclinical results

PremiumThe Fly

Oncolytics reports pelareorep preclinical results

1M ago

Oncolytics price target lowered to $5 from $10 at H.C. Wainwright

PremiumThe FlyOncolytics price target lowered to $5 from $10 at H.C. Wainwright

2M ago

Oncolytics Biotech gains FDA alignment on REO 033 trial

Company Announcements

Oncolytics Biotech gains FDA alignment on REO 033 trial

2M ago

Oncolytics aligns with FDA on path for REO 033 expansion study

The Fly

Oncolytics aligns with FDA on path for REO 033 expansion study

2M ago

ONCY Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

ONCY Upcoming Earnings Report: What to Expect?

3M ago

Oncolytics Biotech Faces Nasdaq Minimum Bid Price Noncompliance

PremiumCompany Announcements

Oncolytics Biotech Faces Nasdaq Minimum Bid Price Noncompliance

3M ago

Oncolytics Biotech gains FDA Fast Track for pelareorep

PremiumCompany Announcements

Oncolytics Biotech gains FDA Fast Track for pelareorep

3M ago

Oncolytics announces FDA Fast Track designation for pelareorep

PremiumThe Fly

Oncolytics announces FDA Fast Track designation for pelareorep

3M ago

Oncolytics Biotech advances REO 033 colorectal cancer program

PremiumCompany AnnouncementsOncolytics Biotech advances REO 033 colorectal cancer program

3M ago

Oncolytics provides clinical, regulatory update on REO 033

The Fly

Oncolytics provides clinical, regulatory update on REO 033

3M ago

Oncolytics Biotech Secures New Pelareorep Manufacturing Patent

Company Announcements

Oncolytics Biotech Secures New Pelareorep Manufacturing Patent

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >